Stryker affirms 2013 guidance, offers limited glimpse of Mako plans
Stryker Corp. CEO Kevin Lobo affirms the medtech firm's 2013 outlook for an audience at the J.P. Morgan Healthcare conference and offers a limited glimpse into the blockbuster buyout of robotic surgery device maker Mako Surgical.
Stryker CEO Kevin Lobo told an audience at the J.P. Morgan Healthcare conference this morning that its prior guidance for 2013 still holds true and provided a peek at the blockbuster Mako Surgical acquisition the medtech company closed 3 weeks ago.
Organic revenue growth is still expected to be between 4.4% and 5.5%, Lobo said today in San Francisco, with adjusted earnings per share coming in the $4.20-$4.26 range.
Stryker had $5.14 billion in net cash as of Sept. 30, 2013, he said.